BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	nilotinib Sensitive: A1 - Approval nilotinib Sensitive : A1	nilotinib Sensitive: A1 - Approval nilotinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	bosutinib Sensitive: A1 - Approval bosutinib Sensitive : A1	bosutinib Sensitive: A1 - Approval bosutinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
BCR-ABL1 V299L	Acute Lymphocytic Leukemia	BCR-ABL1 V299L	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 F317I	Acute Lymphocytic Leukemia	BCR-ABL1 F317I	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 V299L	Chronic Myeloid Leukemia	BCR-ABL1 V299L	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2	bosutinib Resistant: A2 - Guideline bosutinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
BCR-ABL1 E255V	Acute Lymphocytic Leukemia	BCR-ABL1 E255V	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
BCR-ABL1 F317L	Chronic Myeloid Leukemia	BCR-ABL1 F317L	Chronic Myeloid Leukemia	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2	dasatinib Resistant: A2 - Guideline dasatinib Resistant : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 G250E	Acute Lymphocytic Leukemia	BCR-ABL1 G250E	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2

BCR (BCR Activator Of RhoGEF And GTPase)

Associations(290)

Associations
(290)